Access & Affordability

Access & Affordability

XPHOZAH is available for all patients regardless of insurance†

How to Prescribe

Prescribing XPHOZAH is simple.

Send XPHOZAH prescriptions to:

Transition Pharmacy

E-prescribe

Transition Pharmacy Services, LLC
NPI #: 1336325265

Call

877-527-3927 Option 1

Fax

877-594-4906
Use your own Rx or our prescription form

OR

Always include your patient’s dialysis center on prescriptions and remind them to respond to calls or texts from the specialty pharmacy at each refill so XPHOZAH can be shipped directly to their home.

Help patients save with the XPHOZAH Savings Program

$0‡
With copay support automatically applied, patients may pay as little as $0‡ per 30- or 90-day prescription.

Patient Support

Ardelyx Assist Logo

ArdelyxAssist is here to help.

Get access to tools and services to simplify prescribing, access, and patient support.

Dedicated Team Support

A single point of contact for questions and guidance

Cost & Coverage Support

Explore options to help patients afford XPHOZAH

Prior Authorization Support

Assistance navigating prior authorization requirements

Prescription Follow-Up

Support smooth and timely prescription processing

Patient Assistance

Answer patient questions related to access and affordability

Benefits Investigation

Confirm coverage and eligibility for your patients

For questions about access, affordability, or program information, call ArdelyxAssist at 877-527-3927 Option 2, or fill out the form to request a callback.

Resources

Find helpful resources for you and your patients

Xphozah Prescription Form

Prescription Form

Sample Letter of Medical Necessity

Letter of Medical Necessity

XPHOZAH Patient Consent Form

Patient Consent Form

XPHOZAH Patient Starter Guide

Patient Starter Guide

XPHOZAH Medicare Part D Coverage Guide

Medicare Part D Coverage Guide

XPHOZAH Access Step-By-Step Guide

Access Step-by-Step Guide

FAQs

Get answers to frequently asked questions about XPHOZAH

How can I access XPHOZAH? 
To access XPHOZAH, you as the prescriber decide, based on your clinical judgment, which patients should be on XPHOZAH. Write and send XPHOZAH prescriptions to Transition Pharmacy, the ArdelyxAssist specialty pharmacy partner. You can e-prescribe using NPI #: 1336325265, call 877-527-3927 Option 1, or fax the prescription form to 877-594-4906. Or, if you have a relationship with a preferred specialty pharmacy in our network, you can use them instead.
Is XPHOZAH covered by Medicare Part D? 
While Medicare Part D is not currently covering binders or XPHOZAH, XPHOZAH continues to be available. Send XPHOZAH prescriptions to Transition Pharmacy, the ArdelyxAssist specialty pharmacy partner or through any specialty pharmacy within our Specialty Pharmacy Network. Medicare Fee-for-Service and Medicare Advantage patients will be evaluated by ArdelyxAssist and enrolled in the Patient Assistance Program§ if eligible.
How is XPHOZAH covered for different insurance types?
XPHOZAH is available for all patients regardless of insurance.† Transition Pharmacy and ArdelyxAssist work directly with the plan to determine options to help ensure patients can receive XPHOZAH. If access is not available or if the patient cannot afford XPHOZAH, ArdelyxAssist will evaluate eligibility to receive XPHOZAH at no cost through the Patient Assistance Program.§
My patients are having trouble accessing XPHOZAH, what should I do?
ArdelyxAssist can help troubleshoot next steps, coordinate with the Pharmacy, and help move the prescription forward. Call ArdelyxAssist at 877-527-3927 and select Option 2 or contact your Zone Access Manager directly.
What financial assistance programs are available for XPHOZAH?
With the XPHOZAH Savings Program, copay support is automatically applied so patients may pay as little as $0‡ per 30- or 90-day prescription. If access is not available or if the patient cannot afford XPHOZAH, ArdelyxAssist will evaluate patient eligibility to receive XPHOZAH at no cost through the Patient Assistance Program.§ If you have any questions or need support with access or affordability, call ArdelyxAssist at 877-527-3927 and select Option 2 or contact your Zone Access Manager directly.
Do I have to get XPHOZAH through my dialysis organization?
No. Unlike binders that are distributed by dialysis organizations, XPHOZAH is not distributed by dialysis organizations. Prescribe to Transition Pharmacy or the XPHOZAH Specialty Pharmacy Network.

*Partial year 2025 industry data avg PA approval rate and weighted avg out-of-pocket.

†Patients must have a valid, on-label prescription.

‡Terms and conditions apply. For patients with commercial insurance.

§Patient needs to apply and be accepted into the assistance program.

RELATED LINKS

Dosing

Video Hub

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Close

Connect with us for more information and continued updates about XPHOZAH.

Fill out the information below to register for updates.

*Required field.

Close

Close

×

You are now leaving this site

This link will take you to a different site that is owned and operated by an independent third party to which the Ardelyx Privacy Policy does not apply.

Are you sure you want to continue?